Abstract
BackgroundWe wished to estimate the proportion of patients with breast cancer eligible for an exclusive targeted intraoperative radiotherapy (TARGIT) and to evaluate their survival without local recurrence.MethodsWe undertook a retrospective study examining two cohorts. The first cohort was multicentric (G3S) and contained 7580 patients. The second cohort was monocentric (cohort 2) comprising 4445 patients. All patients underwent conservative surgery followed by external radiotherapy for invasive breast cancer (T0–T3, N0–N1) between 1980 and 2005. Within each cohort, two groups were isolated according to the inclusion criteria of the TARGIT A study (T group) and RIOP trial (R group).In the multicentric cohort (G3S) eligible patients for TARGIT A and RIOP trials were T1E and R1E subgroups, respectively. In cohort number 2, the corresponding subgroups were T2E and R2E. Similarly, non-eligible patients were T1nE, R1nE and T2nE, and R2nE.The eligible groups in the TARGIT A study that were not eligible in the RIOP trial (TE–RE) were also studied. The proportion of patients eligible for TARGIT was calculated according to the criteria of each study. A comparison was made of the 5-year survival without local or locoregional recurrence between the TE versus TnE, RE versus RnE, and RE versus (TE–RE) groups.ResultsIn G3S and cohort 2, the proportion of patients eligible for TARGIT was, respectively, 53.2% and 33.9% according the criteria of the TARGIT A study, and 21% and 8% according the criteria of the RIOP trial. Survival without five-year locoregional recurrence was significantly different between T1E and T1nE groups (97.6% versus 97% [log rank =0.009]), R1E and R1nE groups (98% versus 97.1% [log rank =0.011]), T2E and T2nE groups (96.6% versus 93.1% [log rank <0. 0001]) and R2E and R2nE groups (98.6% versus 94% [log rank =0.001]). In both cohorts, no significant difference was found between RE and (TE–RE) groups.ConclusionsAlmost 50% of T0-2 N0 patients could be eligible for TARGIT.
Highlights
We wished to estimate the proportion of patients with breast cancer eligible for an exclusive targeted intraoperative radiotherapy (TARGIT) and to evaluate their survival without local recurrence
We wished to evaluate and compare survival without local recurrence or locoregional recurrence among patients eligible and ineligible for TARGIT according to the criteria of the two trials mentioned above. This was a retrospective study examining two cohorts of patients who had undergone conservative surgery followed by external radiotherapy for invasive, non-metastatic and non-inflammatory Breast cancer (BC)
The second cohort was monocentric. It consisted of 4445 patients treated at the Institut Paoli Calmettes (IPC) from 1980 to 2005 by conservative surgery for tumors of stage T0–T3, N0 or N1 with biopsy of the sentinel node associated or not with axillary dissection, or alternatively with immediate axillary dissection
Summary
We wished to estimate the proportion of patients with breast cancer eligible for an exclusive targeted intraoperative radiotherapy (TARGIT) and to evaluate their survival without local recurrence. Breast cancer (BC) is the leading cancer worldwide in terms of incidence, with 1.38 million new cases diagnosed in 2008 (23% of all cancers). It is the most frequent cancer in “developed” and “developing” countries [1]. It has enabled BC to be diagnosed at an early stage, thereby allowing the possibility of conservative surgery. Several studies have shown that in conservative surgery of an invasive cancer, adjuvant radiation of the breast and surgical site significantly increases survival without recurrence and has an impact on overall survival [2]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
